Study of IMC-P115C in Advanced PRAME-Positive Cancers

Summary

Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.

Timeline

Start

2024-11-07

Primary completion

2027-09-30

Completion

2029-08-30

Drugs

Indications